Korro Bio
KRRO on Nasdaq. Pharmaceutical preparations. Market value $187m.
Price checks use the past 12 months to September 2026. Quality checks use five annual reports, the latest for the year to December 2025.
We can't read total debt from the filing, so debt is left out.
Should I look at this?
Not a fit for our list right now
Why it could be worth it
Nothing stands out yet.
See Health care stocks that passed both tests
This is not advice. Check the numbers below.
For every $100 of what the whole company costs, it produced $-38.21 of spare cash in the past 12 months. A savings account pays about $4.
The filings do not give us enough to work this out.
The filings do not give us enough to work this out.
Quality score: 20 of 100. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.
$12.18 a share, 134% above its 1-year low
Over the past year the price has ranged from $5.20 to $17.35.
Pays no dividend
Prices from Friday’s close (20 November).
Five years of cash, in billions
| Revenue | |||||
| Revenue | $14m | $0 | $0 | $2m | $6m |
| Operating margin | |||||
| Operating margin | -597.3% | n/a | n/a | -4047.1% | -1906.4% |
| Debt to equity | |||||
| Debt to equity | n/a | n/a | n/a | n/a | n/a |
| Shares outstanding | |||||
| Shares outstanding | 0.04bn | 0.04bn | 0.01bn | 0.01bn | 0.01bn |
Health checks
- Free cash flow positive0 of 5 years
- Accounting checksSkipped: company is not yet profitable
- DebtUnknown
- Revenue growth, five yearsShrinking, 29.6% a year
- Buying back its own sharesYes, 61% fewer since 2021
The quarter to September 2026
How the business did, compared with the same quarter a year earlier.
- Sales: $0 last quarter, down 100% on a year ago.
- A loss of $18 million, compared with a loss of $18 million a year ago.
- It loses 8467 cents on each $1 of sales, compared with 1282 cents a year earlier.
- Over the past 12 months it spent $64 million more cash than it brought in, compared with $70 million a year earlier.
- 90% more shares than a year ago. Each share owns a bit less of the company.
- Sales did not grow on a year ago in any of the last 4 quarters.
| Quarter to | Amount |
|---|---|
| December 2024 | $2m |
| March 2025 | $3m |
| June 2025 | $1m |
| September 2025 | $1m |
| December 2025 | $1m |
| March 2026 | $0 |
| June 2026 | $0 |
| September 2026 | $0 |
| Quarter to | Amount |
|---|---|
| December 2024 | -$21m |
| March 2025 | -$23m |
| June 2025 | -$26m |
| September 2025 | -$18m |
| December 2025 | -$50m |
| March 2026 | -$20m |
| June 2026 | -$19m |
| September 2026 | -$18m |
From the company's quarterly reports to the SEC.
Dates
- Next results (estimated)
- n/a
- Last annual report (10-K)
- 12 March 2026
- Next quarterly (estimated, 10-Q)
- 4 February 2027
Who owns it
None of the long-term investors we follow own it. 107 funds in all.
Largest holders overall
- Lynx1 Capital Management LP$20m
- Nantahala Capital Management$17mAdded
- NEA Management Company$17m
- Venrock Adviser$13m
- Atlas Venture Life Science Advisors$13mCut
- Balyasny Asset Management L.P.$13mCut
- BlackRock$11mAdded
- Affinity Asset Advisors$9m
- Adage Capital Partners GP, L.L.C.$7mAdded
- ADAR1 Capital Management$7m
From 13F filings for the quarter ended 30 June 2026.
Big holders and activists
10 investors own more than 5%.
- Lynx1 Capital Management LPPassive investorat least 10.7%+2.9 pts(filed with 1 related holder)Since 31 March 2026
- Venrock Healthcare Capital Partners III, L.P.Passive investorat least 9.9%0.0 pts(filed with 6 related holders)Since 30 September 2026
- New Enterprise Associates 17, L.P.Passive investorat least 9.9%(filed with 11 related holders)Since 10 March 2026
What they said
NEA 17 acquired the NEA 17 Shares for investment purposes. Information with respect to the 2026 Private Placement set forth in Item 3 above is incorporated herein by reference to the extent responsive to this Item 4. Subject to the Registration Rights Agreement, the 2024…
Read the filing - Adage Capital Management, L.P.Passive investorat least 6.8%(filed with 2 related holders)Since 30 September 2026
- Nantahala Capital Management, LLCPassive investorat least 6.4%(filed with 2 related holders)Since 31 December 2025
- BALYASNY ASSET MANAGEMENT L.P.Passive investorat least 5.9%−0.7 pts(filed with 4 related holders)Since 30 September 2026
- Atlas Venture Fund XI, L.P.Passive investorat least 4.9%(filed with 5 related holders)Since 24 June 2026
- Citadel Advisors LLCPassive investorat least 3.9%(filed with 6 related holders)Since 31 December 2024
- Deep Track Capital, LPPassive investorat least 3.0%(filed with 2 related holders)Since 30 June 2025
- Point72 Biotech Private Investments, LLCPassive investorat least 1.9%−3.8 pts(filed with 5 related holders)Since 31 March 2026
- BlackRock, Inc.Passive investorSold down below 5%Since 30 September 2026
- FMR LLCPassive investorSold down below 5%Since 31 December 2025
- AllianceBernstein L.P.Passive investorSold down below 5%Since 30 June 2025
- The Vanguard GroupPassive investorSold down below 5%Since 13 March 2026
- DRIEHAUS CAPITAL MANAGEMENT LLCPassive investorSold down below 5%Since 31 December 2025
| Holder | Stake | Since | |
|---|---|---|---|
Lynx1 Capital Management LP Passive investor | at least 10.7%+2.9 pts (filed with 1 related holder) | 31 March 2026 | |
Venrock Healthcare Capital Partners III, L.P. Passive investor | at least 9.9%0.0 pts (filed with 6 related holders) | 30 September 2026 | |
New Enterprise Associates 17, L.P. Passive investor | at least 9.9% (filed with 11 related holders) | 10 March 2026 | What they saidNEA 17 acquired the NEA 17 Shares for investment purposes. Information with respect to the 2026 Private Placement set forth in Item 3 above is incorporated herein by reference to the extent responsive to this Item 4. Subject to the Registration Rights Agreement, the 2024… Read the filing |
Adage Capital Management, L.P. Passive investor | at least 6.8% (filed with 2 related holders) | 30 September 2026 | |
Nantahala Capital Management, LLC Passive investor | at least 6.4% (filed with 2 related holders) | 31 December 2025 | |
BALYASNY ASSET MANAGEMENT L.P. Passive investor | at least 5.9%−0.7 pts (filed with 4 related holders) | 30 September 2026 | |
Atlas Venture Fund XI, L.P. Passive investor | at least 4.9% (filed with 5 related holders) | 24 June 2026 | |
Citadel Advisors LLC Passive investor | at least 3.9% (filed with 6 related holders) | 31 December 2024 | |
Deep Track Capital, LP Passive investor | at least 3.0% (filed with 2 related holders) | 30 June 2025 | |
Point72 Biotech Private Investments, LLC Passive investor | at least 1.9%−3.8 pts (filed with 5 related holders) | 31 March 2026 | |
BlackRock, Inc. Passive investor | Sold down below 5% | 30 September 2026 | |
FMR LLC Passive investor | Sold down below 5% | 31 December 2025 | |
AllianceBernstein L.P. Passive investor | Sold down below 5% | 30 June 2025 | |
The Vanguard Group Passive investor | Sold down below 5% | 13 March 2026 | |
DRIEHAUS CAPITAL MANAGEMENT LLC Passive investor | Sold down below 5% | 31 December 2025 |
From Schedule 13D and 13G filings: anyone owning more than 5% must file one.
What insiders did
No insider bought shares on the open market in the last 12 months. 6 sold $7m, $6m of it under preset trading plans.
- FORMELA JEAN FRANCOISDirectorSoldunder a preset trading plan
- Date
- 12 November 2026
- Shares
- 40,045
- Price
- $14.30
- Value
- $572,644
- FORMELA JEAN FRANCOISDirectorSoldunder a preset trading plan
- Date
- 11 November 2026
- Shares
- 26,587
- Price
- $15.08
- Value
- $400,966
- FORMELA JEAN FRANCOISDirectorSoldunder a preset trading plan
- Date
- 14 September 2026
- Shares
- 38,490
- Price
- $14.12
- Value
- $543,479
- FORMELA JEAN FRANCOISDirectorSoldunder a preset trading plan
- Date
- 11 September 2026
- Shares
- 10,200
- Price
- $13.99
- Value
- $142,698
- Dolan OliverSenior Vice President, FinanceSoldunder a preset trading plan
- Date
- 11 September 2026
- Shares
- 5
- Price
- $13.72
- Value
- $69
- Dolan OliverSenior Vice President, FinanceSoldunder a preset trading plan
- Date
- 9 September 2026
- Shares
- 6
- Price
- $13.60
- Value
- $82
- Dolan OliverSenior Vice President, FinanceSoldunder a preset trading plan
- Date
- 8 September 2026
- Shares
- 7,347
- Price
- $13.51
- Value
- $99,286
- FORMELA JEAN FRANCOISDirectorSoldunder a preset trading plan
- Date
- 26 August 2026
- Shares
- 300
- Price
- $13.96
- Value
- $4,188
- FORMELA JEAN FRANCOISDirectorSoldunder a preset trading plan
- Date
- 19 August 2026
- Shares
- 28,468
- Price
- $14.00
- Value
- $398,552
- FORMELA JEAN FRANCOISDirectorSoldunder a preset trading plan
- Date
- 11 August 2026
- Shares
- 2,143
- Price
- $13.96
- Value
- $29,916
| Date | Who | Did | Shares | Price | Value |
|---|---|---|---|---|---|
| 12 November 2026 | FORMELA JEAN FRANCOIS Director | Sold under a preset trading plan | 40,045 | $14.30 | $572,644 |
| 11 November 2026 | FORMELA JEAN FRANCOIS Director | Sold under a preset trading plan | 26,587 | $15.08 | $400,966 |
| 14 September 2026 | FORMELA JEAN FRANCOIS Director | Sold under a preset trading plan | 38,490 | $14.12 | $543,479 |
| 11 September 2026 | FORMELA JEAN FRANCOIS Director | Sold under a preset trading plan | 10,200 | $13.99 | $142,698 |
| 11 September 2026 | Dolan Oliver Senior Vice President, Finance | Sold under a preset trading plan | 5 | $13.72 | $69 |
| 9 September 2026 | Dolan Oliver Senior Vice President, Finance | Sold under a preset trading plan | 6 | $13.60 | $82 |
| 8 September 2026 | Dolan Oliver Senior Vice President, Finance | Sold under a preset trading plan | 7,347 | $13.51 | $99,286 |
| 26 August 2026 | FORMELA JEAN FRANCOIS Director | Sold under a preset trading plan | 300 | $13.96 | $4,188 |
| 19 August 2026 | FORMELA JEAN FRANCOIS Director | Sold under a preset trading plan | 28,468 | $14.00 | $398,552 |
| 11 August 2026 | FORMELA JEAN FRANCOIS Director | Sold under a preset trading plan | 2,143 | $13.96 | $29,916 |
From Form 4 filings: insiders must report trades in their own company's shares within two days.
Warning signs in its filings
Problems the company itself reported to the SEC, in its own words.
None of the warning signs we check for were found.
We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.
We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 12 Mar 2026, plus the 10-Q filed 5 Nov 2026 and 8 later 8-Ks.
A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.
What could go wrong
- Sales have shrunk: 29.6% a year.
Whether the price already reflects the risks is what the deep dive is for.
The deep dive
Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.
- What the business is worth, as a range, and the margin of safety at today’s price
- Prices to start buying, buy, and buy hard
- The three things that would make this a mistake
- Every number footnoted to the filing it came from
Your first deep dive is free.
Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.